Life Sciences Archive » February, 2019

Life Sciences - February, 2019

342 articles

• Del. Chancellor Accused Of Not Disclosing Conflict While Atty
• CIT Gives Duty Break To McKesson's Drug Dispensers
• Relators Claim No Notice Of Dismissal In $70M FCA Suit
• Original FTC V. Actavis Case Ends With AbbVie AndroGel Deal
• DLA Piper Adds Partner To Miami Corporate Practice
• Fed. Circ. Clears Perrigo's Generic Pepcid In Patent Case
• Abbott Test Strip Fight Triggers Defense Duty: Wis. Justices
• Alaska Republican Floats Bill To Let Tribes Regulate Marijuana
• Keryx Says It Didn't Mislead Investors On Drug's Production
• Teva Can't Beat Whistleblowers' FCA Suit Over Paid Speakers
• UK Accuses Drugmakers Of Anti-Competitive Agreements
• CVS Falsely Told Docs Patients Wanted Scripts, Suit Says
• 3rd Circ. Limits Scope Of FTC Judicial Enforcement Authority
• Stryker Beats Ex-Sales Rep's Age Bias Suit Over Firing
• Genetics Co. Raises $191M In Venture Funding
• Risks Of Promoting Products As 'Safe' For Pregnant Women
• Kaleido Biosciences Prices $75M IPO Below Range
• Bristol-Myers Fights Investor Pushback On $74B Celgene Buy
• J&J Rep Pressed On Internal Tests In Talc Cancer Trial
• Monsanto MDL Judge Sanctions 'Steely' Atty, Explains Remark
• Teva Must Pay $500K In Legal Bills Over Ex-Exec's Firing
• Teva Can't Fight FDA's New Generic-Exclusivity Policy: Judge
• University Wants IP Back After Prof. Allegedly Stole Research
• Parts Of Skin Care Patents Likely Invalid But No PTAB Review
• Genentech Profits Off Wasteful Cancer Drug Vials, Suit Says
• 7th Circ. Says Imaging Co. Can't Nix $15M Cancer Suit Award
• Hikma Urges Justices To Eye Ruling On Medical Treatment IP
• Pomerantz To Rep Investors In Acadia Drug Deaths Case
• Gibson Dunn, Latham Steer Ultragenyx's $304M Follow-On
• Real Estate Rumors: Bridge, Albert Behler, Lightstone
• Novartis Ducks More Damages In Whistleblower Suit
• Sarepta Inks $165M Myonexus Buy In Gene Therapy Deal
• Merck Launches $6B Threat To Versum-Entegris Deal
• What To Expect From USPTO On Patent Term Post-Supernus
• Banks Should Prepare For Federal Marijuana Legalization
• Blackstone Forms New Biotech With Initial $250M Investment
• Deals Rumor Mill: ChemChina, Cerberus, Nexon
• Better Late Than Never? Not So For Class Cert. Appeals
• Monsanto MDL Judge Slams Female Atty's 'Steely' Composure
• Bayer Beats Certified Class In $600M Vitamin Labeling Row
• 3rd Circ. Kills Lotion TM Case Against Cetaphil Maker
• 9th Circ. Affirms Ex-Bio-Rad GC's $8M Whistleblower Win
• AbbVie Investors Want Records On Testosterone Marketing
• Lilly Gets PTAB To Review 6 Teva Migraine Biologic Patents
• Chemical Co. Sued For Allegedly Abusing Retirement Plans
• Big Pharma Largely Unscathed After Capitol Hill Showdown
• Tech, Life Science IPOs Set To Remain Strong In 2019
• Oyster Pharma Sees $93M Funding Round For Dry Eye Drugs
• NECC Execs Say Conspiracy Convictions 'Legally Impossible'
• Supreme Court Urged Once Again To Clarify Key FCA Dispute
• Bristol-Myers Ends Abilify MDL With Confidential Settlement
• Court 'Science Days' May Not Benefit All Parties Equally
• Novartis Hit With $1.5M Whistleblower Verdict In NJ
• Weeding Out Meritless Claims In Multidistrict Litigation
• Biz Groups Mobilize For NAFTA 2.0 As Trump Presses Dems
• Missed Appeal Deadline Can't Be Extended, Justices Rule
• Amgen's Cholesterol Drug Patents Are Valid, Jury Says
• 'Sugar Bear Hair' Maker Sues Over Knockoff Gummy Vitamins
• Senators Must Get To The Root Of High Drug Prices
• Don't Advance Drug Antitrust Claims, Express Scripts Urges
• Hogan Lovells Nabs Life Sciences IP Duo From Venable
• Vanda Hid Off-Label Fraud Scheme From Investors, Suit Says
• Pharmas Inflating Info Leak To Unseat Patent Loss, Rival Says
• Monsanto MDL Judge Threatens Atty Sanctions As Trial Starts
• City Bellwethers In Opioid MDL Carved Out, Delayed
• Calif. County Can't Get Deal Over Stroke Medication Tossed
• Amarin Hit With Stock Drop Suit Over Drug Trial Results
• Patent-Busting A Hard Sell For Public Health Activists
• German Dialysis Firm Fresenius Notches Deal In FCPA Probe
• FTC Can't Challenge Past Conduct In Court, 3rd Circ. Says
• Winning PTAB Args Should Be OK For Court, Fed. Circ. Hears
• Sinovac Uses Poison Pill To Weaken Dissident Shareholders
• Bayer Seeks Fees After $155M Hemophilia Drug IP Verdict
• Boehringer Must Show How IP 'Thicket' Blocked Humira Rival
• 'The Spiel' Helped Insys Get Opioid Spray Paid For, Exec Says
• Kirkland Steers Close Of $2.1B SK Capital Fund
• 4 Firms Guide Ipsen's $1.3B Clementia Pharma Deal
• Diplomat Pharmacy Misled Investors About New Venture: Suit
• Venture-Backed Medical Device Biz Launches $75M IPO
• Goodwin, Davis Polk Lead Roche's $4.8B Spark Buy
• Manufacturers Can Curb Influencers' Fanciful Product Claims
• 3 Firms Steer GE's $21B Sale Of Biopharma Unit To Danaher
• Consultants Aim To Send GSK Probe Suit Back To State Court
• Lawmakers Eye Biosimilar-Delay Deals, But None Are Here Yet
• 3 Things To Watch At Monsanto's Roundup Bellwether Trial
• Generics Cos. Say No Grand Conspiracy In Price-Fixing MDL
• Drugmaker To Pay $4M To End Claims It Dodged FDA Fees
• Texas Pharma Sales Rep Pleads Guilty To $8M Fraud
• Deals Rumor Mill: Sika, Berkshire Hathaway, Centogene
• Synergy Pharma Faces Pushback Over Ch. 11 Plan Releases
• Neurotech Startup Closes $28M Round Led By Alphabet Unit
• Novartis, Express Scripts Beat Kickback Suit Over Discounts
• FDA Focus: What Sidley Austin's Practice Chair Is Watching
• Insys Rode 'The Gray Line' To Mislead Insurers, Exec Says
• Baylor Med School Denied Attys' Fees In Cancer IP Row
• US Scientists Belong On Cancer Patents, Judge Hears
• Greenspoon Marder Unit, Squire Patton Back Pot Roundtable
• WuXi Accused Of Shorting Investors In Go-Private Deal
• Amgen, Teva Cut Illegal Deal To Pull Generic, Suit Says
• Health Hires: DLA Piper, Baker McKenzie, Taft, Buchalter
• A Holistic Approach To Compliance For Cannabis Cos.
• 3 Lessons From A Crypto Mock Trial
• Arizona High Court Puts Stengel Claims In Doubt
• Tracing Puerto Rico's Journey Through Bankruptcy
• UK's SFO Drops Corruption Probes Into Rolls-Royce, GSK
• Jury Verdict Clearing Allergy Advocacy Group Stands: Judge
• Ex-Novartis Exec's Whistleblower Claim A Lie, NJ Jury Told
• J&J's Expert Tells Calif. Jury Talc Doesn't Cause Cancer
• Lipocine Hit By Investor With Testosterone Drug 'Scheme' Suit
• 2nd Circ. Saves FTC Oversight Of Red-Hot Memory Aid Sector
• Specialty Pharma Co.'s $34M Ch. 11 Financing OK'd
• Rare Disease Biotech Mereo BioPharma Pulls $70M US IPO
• Onyx's Patent Agent Privilege Claim Fails In Cancer Drug Row
• Canada Closes Antitrust Probe Into Janssen Over Biosimilars
• Ex-Biotech Exec Settles SEC Insider-Trading Case For $148K
• NY, Fla. Buyers Favored For Cert. In Gerber False Ad Suit
• Amgen Asks Fed. Circ. To Uphold $70M Hospira IP Verdict
• MPM Capital Closes Biotech-Focused Fund With $400M
• 2 Firms Steer Merck's $300M Immune Design Deal
• HHS Is Embracing A Broader Vision Of Health Care
• Explainability: Where AI And Liability Meet
• ResMed, Fisher & Paykel End Sleep Mask Patent Fight
• Squire Patton Boggs Snags Patent Prosecutor Todd Lorenz
• J&J Subpoenaed Over Claims Of Asbestos In Baby Powder
• FTC's Teva Settlement A Sign Of Enforcement Evolution
• 2nd Circ. Judge Must Exit FTC Case, Supplement Co. Says
• Fed. Circ. DQs Katten Over Conflicts In Mylan Patent Case
• Fresenius Asks Chancery For Fast Akorn Damages Ruling
• Amphastar Says Rivals' Patent Loss Is Antitrust Ammo
• OptumRx Owes Workers' Comp Fund $16M, Ohio AG Says
• Monsanto Gets Gift With Two-Stage Roundup Bellwether
• Calif. AG Pushes Bill Banning Generic Drug Pay-For-Delay
• Atty-Turned-Fraudster Loses 2nd Bid To Access SEC Files
• Judge Skeptical Of Ex-Novartis Exec's Whistleblower Claims
• Drug Co. Peloton Snags $150M In Funding For Cancer Trials
• A Chat With McDermott COO John Yoshimura
• Bristol-Myers Gives FTC More Time To Review $74B Merger
• Boston Scientific Says 50K Mesh Settlements Almost Final
• 2nd Recent FTC Split OKs Fresenius $2B Merger With Fixes
• DOJ Says Shuttered Abbott Unit Engaged In Kickback Scheme
• High Court Won't Block Dr. Reddy's Opioid Treatment
• Judge Limits Evidence For Roundup Bellwether Trial
• 'Absurd' To Argue PTAB Wins Bar Patent Cases: Generics Cos.
• Clyde & Co. Atty Describes Cancer's Shadow In J&J Talc Trial
• Opioid MDL Atty Gets Heat For Ripping Purdue 'Scumbags'
• Biotech Co. Says $3.6M Award Wrongly Calculated
• Chancery Awards Legal Costs In DAVA-Endo Merger Case
• Generics Cos. To Face Most State Claims In Price-Fixing MDL
• NJ Pain-Drug Maker Hits Ch. 11 With $75M Purchase Offer
• High Court Won't Hear Fight Over Md. Price-Gouging Law
• FTC Pens New Deal With Teva On Reverse-Payment Claims
• Mass. Biopharma Co. Launches IPO That Could Raise $120M
• Cochlear Targets US Rival In Patent Suit Over Hearing Implant
• Justices Reject Mylan's Challenge To 'Tactical' Drug Patenting
• The Problem With 'Optimal' Diversity
• The $1B Question: Can Puerto Rico Afford Its Bankruptcy Bills?
• Puerto Rico's Law Firms Find Their Footing After Disaster
• AbbVie, Eli Lilly Beat Insurer's RICO Suit in Testosterone MDL
• FTC Wants More Info On Boston Scientific's £3.3B BTG Buy
• Investor Reaffirms Suit Accusing Akorn Execs Of Deceit
• Ex-FDA Atty Joins McDermott Will & Emery's DC Office
• Ex-Vinson & Elkins Atty Joins Pillsbury In NY
• Trump's Drug Rebate Ban Faces Fraught Legal Path
• 'We're All Going To Jail,' Ex-Insys CEO Says He Heard At Work
• Restasis Patent Redo Bid 'Inappropriate,' Fed. Circ. Told
• Lamictal Case Won't Be Paused For Class Cert. Appeal
• Insulin Giants Beat RICO Claims Brought By Patients
• Gov't Opioid Suits Hide Attorneys' Personal Interests
• WilmerHale-Led Stealth Biotherapeutics Debuts With $78M IPO
• ITC Clears Japanese Dental Co. In Rival's Patent Suit
• A First Look At New HHS Prescription Drug Safe Harbors
• Coca-Cola-Tied Engineer Stole IP For Chinese Co., DOJ Says
• AbbVie Execs Hit By Another Suit Over Drug, Stock Schemes
• Mo. High Court Lets J&J Move Talc Trial To St. Louis County
• Retailer Shopko Seeks To Investigate McKesson In Ch. 11
• UPS Suit Delivers Warning To Cannabis Co.: Stop Using Marks
• Walgreens, Kroger Slam J&J's Challenge To Antitrust Claims
• Bankrupt Imerys Dropped From Dying Woman's J&J Talc Trial
• Insys Directors Say Criminal Trial Still Stops Chancery Case
• 2 VC-Backed Health Care Cos. Price IPOs Totaling $145M
• Nektar Hit With Derivative Suit Over Drug Trial Results
• Reps Challenge FDA On Foreign Drug Monitoring After Recalls
• Ex-Insys CEO Says Founder Called Him Company's 'Fall Guy'
• Subsys-Prescribing Doc Cops To Kickback Conspiracy
• Perrigo, Ex-Execs Left 'Financial Bloodbath,' $555M Suit Says
• Reasons To Limit Inventor Testimony In Hatch-Waxman Cases
• Gene-Editing Co. Cibus Delays IPO, Citing Market Conditions
• Investors Inject $125.5M Into Early Cancer Detection Co.
• DC Firm Helped Ranbaxy Avoid FDA Scrutiny, RICO Suit Says
• Brain Fingerprinting Tech Row Sent To Arbitration
• VIDEO: Insys Exec Dances As Bottle Of Fentanyl Spray
• Covington Snags Ex-Wilson Sonsini Tech M&A Pro In Calif.
• J&J Talc Supplier Seeks Ch. 11 Amid Asbestos Suit Tidal Wave
• Insys Thought It 'Owned' Doctors, Former CEO Testifies
• DOJ Flexes New Muscles In Opioid Fight
• Innovative And Ineligible: Diagnostic Patents At Fed. Circ.
• How Calif. Cannabis Rules Will Impact Investors And Lenders
• Lowered Bar For BIPA Lawsuits Will Raise Insurance Issues
• Cravath, Wachtell Advise On J&J's $3.4B Auris Health Deal
• Big Pharma Peers Won't Follow J&J On Price Transparency
• 3 Takeaways From The Latest Ax Of A Diagnostic Patent
• Proposed Opportunity Zone Regs Hazy On Marijuana Projects
• Fed. Circ. Says UK DNA Sequencers Don't Infringe IP In US
• Ex-Insys CEO Says Founder Demanded Aggressive Marketing
• Deals Rumor Mill: DoorDash, Rivian, BASF
• PTAB Won't Hear Dr. Reddy's Challenge To Revlimid Patents
• Tibet Pharma Observers Not Liable In IPO Row, 3rd Circ. Told
• VC-Backed Biopharma Co. Anchiano Launches $30.5M IPO
• Fresh Takes On Seeking Costs And Fees Under Rule 45
• Alere Dodges New Trial In Drug-Testing Patent Fight
• For Now, Competitive Generic Therapy Exclusivity Is A Mirage
• McKesson Rebuke For Rx Tampering Reaction A First For FDA
• Amphastar GC In On Docs Leak In Antitrust Suit, Cos. Say
• Roche To Settle Enzo Biotech IP Fight For $21M
• Texas Atty Can't Arbitrate Malpractice Suit, 1st Circ. Rules
• DOJ Backs Long FCA Filing Limit At Supreme Court
• SD Governor Looks To Stop Industrial Hemp Bill For Now
• Insys Paid For Painkiller Prescriptions, Nurse Tells Jury
• FDA Targets Alzheimer's Products In Supplement Crackdown
• J&J Can Avoid Mandatory-Arbitration Vote, SEC Says
• Monsanto Pegs Cancer On Obesity, Hep C In Roundup MDL
• $785M In Debt, Diagnostics Provider Files For Bankruptcy
• Spain's Competition Watchdog Targets Radiology Drug Makers
• NJ Medical Device Co.'s Ch. 11 OK'd In Delaware
• Collins Says Insider Trading Prosecutors Violated His Rights
• Fed. Circ. Backs J&J Trial Win In Contact Lens Patent Suit
• Retailers At Risk From New Glyphosate Liability Theories
• Judging A Book: Smith Camp Reviews 'Echo Of Its Time'
• ADEA Protections For Outside Applicants Still Up In The Air
• One Woman's Attempt To Rebuild After Hurricane Maria
• 'Now Is The Real Crisis': Puerto Ricans Struggle For Disaster Aid
• Looking To Start Over, Storm-Tossed Lawyers Land In Fla.
• AbbVie Must Detail Efforts To Kneecap Humira Biosimilars
• Top Cases And Developing Trends In FCA Litigation: Part 2
• DOJ Takes 'First Of Its Kind' Action Against Tenn. Pharmacies
• Cut $3.6M From Infringement Verdict, Supplement Co. Asks
• $62B Bayer-Monsanto Deal Gets Final OK Despite Pushback
• 11 Firms To Lead 6 IPOs Aiming To Price Before Feb. Pause
• Health Hires: Locke Lord, Sidley Austin, Butler Snow
• Drugmaker Avadel Gets Boost From Parent In Del. Ch. 11
• USPTO's Take On Reused PTAB Positions May Upend Strategy
• J&J Unit Dodges Suit Over Gastric Band Device Death
• 2nd Circ. Leans FTC's Way In Memory-Booster Battle
• Senate Judiciary Carves Out New IP Subcommittee
• Colgate Dodges Philly Talc Suit Just Before Trial Kickoff
• VC-Backed Gossamer Bio Begins Trading After $276M IPO
• Push To Legalize Cannabis Biz Deductions Made In Congress
• UK Litigation Roundup: Here's What You Missed In London
• The Role Of Data Analytics In Mass Torts
• Arnold & Porter Gets Product Liability Atty Back From FDA
• Top Cases And Developing Trends In FCA Litigation: Part 1
• 6 Of 7 J&J Talc Samples Contained Asbestos, Jury Told
• Bank Wants Out Of Drugmaker MannKind's Stock-Drop Suit
• Fed. Circ. Kills Patent Fight After Momenta Ditches Biosimilar
• Johnson & Johnson To Include Drug Cost Info In TV Ads
• Bitcoin Biz-Linked Pump-And-Dump Schemers To Pay $2.3M
• Zetia Pay-For-Delay MDL Should Press On, Magistrate Says
• Chancery Slashes Bylaw Suit Atty Fees To $50K From $300K
• Womble Bond Dickinson Opens Office In Houston
• Ill. Construction Unions Sue Pharma Cos. Over Opioid Crisis
• 'The Mooch' Talks Mayhem, Con Law, Lessons From Harvard
• Ex-Mass. State Worker Cops To Role In $12.7M Stock Fraud
• Now In Congress: State Of The Union, Border Wall, Syria
• Competition, Not Confiscation, Is Key To Lower Drug Prices
• CMS Price Transparency Push Trails State Initiatives
• Opioid MDL Judge Mulls BakerHostetler DQ, Vents Frustration
• Drugmaker Files Ch. 11, Blames Low-Selling Urination Drug
• J&J 'Captured' Regulators To Hide Talc Asbestos, Jury Told
• Sanitation Issues Spur FDA To Stop Drugmaking At Pharmacy
• Trump Health Care Outreach Gains Little Traction
• Deals Rumor Mill: EQT Partners, Cevian, Cboe Global
• Fed. Circ. Axes Athena Diagnostic Test Patent As Natural Law
• 4th Circ. Upholds PE Firm's $87M Heparin Suit Coverage Win
• Aralez Puts Forward Ch. 11 Plan Isolated From Toprol Sale
• Jefferies Uses New York Law To Escape Texas Investors' Suit
• Don't Force NAFTA Rewrite Vote, Key Dem Tells Trump
• WilmerHale-Led Stealth Biotherapeutics Aims For $81M IPO
• Why Proper Document Redaction May Be An Ethical Duty
• Full Fed. Circ. Won't Review $20M Cialis Marketing Verdict
• Cannabis Case Highlights New Patent Considerations
• State Of The Union Pushes For Drug Price Fixes
• Allergan Wants ITC To Eye Rival Version Of Botox
• Jury Says Takeda Unit Owes Bayer $155M Over Hemophilia IP
• Pharma Co. Seeks Justice Review Over Updating Statements
• Novum Pharma Taps Cash Collateral As It Seeks Ch. 11 Buyer
• It's Déjà Vu As Witness Aids Juror, Prompts Risperdal Mistrial
• Tough Sell On Cancer Link Awaits At 1st Philly Talc Trial
• FTC Permitted To Force Exec Testimony In AndroGel Trial
• Celgene Investor Says Info Scant On $74B Bristol-Myers Union
• GSK Can't Escape MDL Alleging Zofran Caused Birth Defects
• Fed. Circ. Revives Sanofi Bid To Amend Cancer Drug Patent
• Trading Firm Tries To Save $3.6M Int'l Arbitration Award
• Fed. Circ. Appears To Side With Eli Lilly Over Cancer Patent
• Ex-Teva Exec's $5M In Punitive Damages Is Chopped By Cap
• Ex-Akin Gump Atty Leaked Docs In Antitrust Suit, Co. Says
• Bernstein Litowitz To Helm Opko Health Pump-And-Dump Suit
• Puma Biotech Misled Investors About Cancer Trial, Jury Says
• Why I Became A Lawyer: A Refugee's Journey Of Firsts
• Experts Predict Strong 2019 For IPOs Amid Gov't Uncertainty
• GSK Extends Drug Pipeline Push With Up To €3.7B Merck Deal
• DC Boutique Nabs FDA Partner From Baker McKenzie
• 1st Circ. Ponders 'Possible' Meaning In Fidelity Market Case
• Farm Bill Gives Cannabis Companies Room To Grow
• Method-Of-Treatment Patent Eligibility: Step 1 And Done?
• Some Cannabis Restrictions In Fla. Could Soon Be Extinct
• Judge Warns Against Attys 'Feeding' Experts In Roundup MDL
• Drug Co. Reaches $17M Deal In False Claims Act Suit
• USPTO Says Successful PTAB Cases Can't Be Cloned In Court
• Bellwether Jury Awards $3M In Cook Medical Vein Filter MDL
• Delaware AG Can Pursue Fraud Claims Against Opioid Makers
• 11th Circ. Backs Sperm Bank's Win In Sham-Donor Suit
• Pfizer Should Face Label Suit, Robitussin Buyers Say
• McKesson Must Face Omni's FCA Suit Over Drug Skimming
• GSK Wants Chinese Consultants' Probe Claims Arbitrated
• Thermo Fisher's $4.7M Wage Deal Lacks Info, Judge Says
• Par Pharma Seeks To Void Merck Diabetes Drug Patent
• Deals Rumor Mill: Starboard, Smart & Final, Palo Alto
• NYT Article Was Defamation, OSU Scientist Tells 6th Circ.
• Recent Decisions Bode Well For False Claims Act Defendants
• Novum Pharma Opens $53M Del. Ch. 11 With Sale Plan
• 11th-Hour Deal Lets Pfizer Exit As Cancer Patent Trial Begins
• Thoratec Inks $11.9M Deal With Investors In Heart Device Suit
• 4 Tips For Medical Device Cybersecurity
• 3 Cos. Launch IPOs Totaling $250M Amid Early Feb. Rush
• Ex-Abiomed Exec Seeks To Revive $2.1M Wrongful Firing Suit
• Keeping PR Strategy Communications Privileged: Part 2
• A Hard Choice For Abbreviated Biologics License Applicants
• Ex-Pharma CEO Convicted Of $100M Puerto Rico Bank Fraud
• 7th Circ. Decision Overlooks Purpose Of Age Bias Law
• As Puerto Rico Recovers, Courts Heed Lessons Of Disaster
• Alere Settles Investor Claims Over Blood Monitor For $20M
• Calif. Judge Axes Suits Alleging Pradaxa Warnings Inadequate
• Purdue Brass 'Milked' $4B From Opioid Addiction: Mass. AG
• Drug Co. Founders Defend Legal Fees In $20M Chancery Suit
• 10 Firms Will Steer 6 IPOs Raising $724M To Start February
• AGs Want To Unlock Redacted Generic Price-Fixing Complaint
• Ex-Insys Exec Testifies On Blowing Up At Founder
• Target Customers Seek Cert. In B-Vitamin Class Action
• Ex-Stradling Yocca Partner Joins Loeb & Loeb's Tax Practice
• Fed. Circ. Says PTAB Right To Uphold Epilepsy Drug Patent
• Allergan Deal Gets Compounder To Say Drugs Not FDA-OK'd
• Keeping PR Strategy Communications Privileged: Part 1